Solid-state dependent dissolution and oral bioavailability of piroxicam in rats. 2013

Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
Department of Pharmacy, Faculty of Medicine, University of Tartu, Nooruse 1, 50411 Tartu, Estonia. andres.lust@ut.ee

The aim of this study was to gain understanding about the effects of different solid-state forms of a poorly water-soluble piroxicam on drug dissolution and oral bioavailability in rats. Three different solid-state forms of piroxicam were studied: anhydrate I (AH), monohydrate (MH), and amorphous form in solid dispersion (SD). In addition, the effect of a new polymeric excipient Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer) on oral bioavailability of piroxicam was investigated. Significant differences in the dissolution and oral bioavailability were found between the solid-state forms of piroxicam. Amorphous piroxicam in SD showed the fastest dissolution in vitro and a solid-state transformation to MH in the dissolution medium. Despite the presence of solid-state transformation, SD exhibited the highest rate and extent of oral absorption in rats. Oral bioavailability of other two solid-state forms decreased in the order AH and MH. The use of Soluplus® was found to enhance the dissolution and oral bioavailability of piroxicam in rats. The present study shows the importance of solid-state form selection for oral bioavailability of a poorly water-soluble drug.

UI MeSH Term Description Entries
D008297 Male Males
D010894 Piroxicam A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. CP-16171,Feldene,CP 16171,CP16171
D002152 Calorimetry, Differential Scanning Differential thermal analysis in which the sample compartment of the apparatus is a differential calorimeter, allowing an exact measure of the heat of transition independent of the specific heat, thermal conductivity, and other variables of the sample. Differential Thermal Analysis, Calorimetric,Calorimetric Differential Thermal Analysis,Differential Scanning Calorimetry,Scanning Calorimetry, Differential
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D014961 X-Ray Diffraction The scattering of x-rays by matter, especially crystals, with accompanying variation in intensity due to interference effects. Analysis of the crystal structure of materials is performed by passing x-rays through them and registering the diffraction image of the rays (CRYSTALLOGRAPHY, X-RAY). (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Xray Diffraction,Diffraction, X-Ray,Diffraction, Xray,Diffractions, X-Ray,Diffractions, Xray,X Ray Diffraction,X-Ray Diffractions,Xray Diffractions
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
April 2003, Bollettino chimico farmaceutico,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
October 2010, Pharmaceutics,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
October 2016, Colloids and surfaces. B, Biointerfaces,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
April 2007, Drug development and industrial pharmacy,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
June 2018, Drug delivery and translational research,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
March 2013, Colloids and surfaces. B, Biointerfaces,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
April 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
January 2020, International journal of pharmaceutics,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
June 2017, International journal of pharmaceutics,
Andres Lust, and Ivo Laidmäe, and Mirja Palo, and Andres Meos, and Jaakko Aaltonen, and Peep Veski, and Jyrki Heinämäki, and Karin Kogermann
November 2017, Drug development and industrial pharmacy,
Copied contents to your clipboard!